文献速递神经肌肉病神经免疫

FcRn拮抗剂efgartigimod治疗全身型重症肌无力的随机2期研究

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
PubMed 文献 · Neurology · 2019-05-22

这项2期探索性随机双盲安慰剂对照15中心研究纳入24例有抗AChR抗体史且标准治疗稳定的全身型重症肌无力患者,1:1随机接受10 mg/kg IV efgartigimod或安慰剂共4剂。Efgartigimod耐受良好,无严重或重度不良事件,所有用药患者总IgG和抗AChR自身抗体快速下降,4个疗效量表一致显示75%患者快速持久改善。

要点

  • Efgartigimod 10 mg/kg IV每3周4剂在gMG患者中安全耐受,无严重或重度不良事件。
  • 所有efgartigimod治疗患者总IgG和抗AChR自身抗体水平快速下降。
  • 4个疗效量表一致显示75%患者出现快速且持久的疾病改善。

核心结论

  • Efgartigimod在全身型重症肌无力患者中安全且耐受良好。
  • 致病性IgG自身抗体水平下降与疾病改善相关,提示减少致病性自身抗体可能是治疗MG的创新途径。

研究设计与样本

  • 2期探索性随机双盲安慰剂对照15中心研究。
  • 24例有抗AChR自身抗体史且标准治疗稳定的全身型重症肌无力患者1:1随机。
  • efgartigimod组12例接受10 mg/kg IV efgartigimod,3周内共4剂,联合标准治疗;安慰剂组12例。
  • 主要终点为安全性和耐受性,次要终点包括疗效、药代动力学、药效学和免疫原性。

主要发现

  • efgartigimod在所有患者中耐受良好,未报告严重或重度不良事件。
  • 未观察到生命体征或心电图相关变化,efgartigimod与安慰剂不良事件无差异。
  • 所有efgartigimod治疗患者总IgG和抗AChR自身抗体水平快速下降。
  • 4个疗效量表一致显示75%患者出现快速且持久的疾病改善。

关键数值与推荐

  • efgartigimod剂量为10 mg/kg IV,3周内共4剂。
  • 疗效评估包括MG-ADL、QMG、MGC疾病严重程度评分和修订15项MG-QoL量表从基线至第11周变化。
  • 该研究提供Class I证据表明efgartigimod在gMG患者中安全且耐受良好。

临床怎么用

  • 对于标准治疗稳定的全身型重症肌无力且有抗AChR抗体史患者,efgartigimod可作为减少致病性IgG自身抗体的创新治疗选择。
  • 治疗期间应监测总IgG和抗AChR自身抗体水平及疾病严重程度量表变化。

局限性

  • 本研究为2期探索性研究,样本量较小(共24例)。
  • 疗效为次要终点,需进一步更大规模研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate safety and explore efficacy of efgartigimod (ARGX-113), an anti-neonatal Fc receptor immunoglobulin G1 Fc fragment, in patients with generalized myasthenia gravis (gMG) with a history of anti-acetylcholine receptor (AChR) autoantibodies, who were on stable standard-of-care myasthenia gravis (MG) treatment. METHODS: A phase 2, exploratory, randomized, double-blind, placebo-controlled, 15-center study is described. Eligible patients were randomly assigned (1:1) to receive 4 doses over a 3-week period of either 10 mg/kg IV efgartigimod or matched placebo combined with their standard-of-care therapy. Primary endpoints were safety and tolerability. Secondary endpoints included efficacy (change from baseline to week 11 of Myasthenia Gravis Activities of Daily Living, Quantitative Myasthenia Gravis, and Myasthenia Gravis Composite disease severity scores, and of the revised 15-item Myasthenia Gravis Quality of Life scale), pharmacokinetics, pharmacodynamics, and immunogenicity. RESULTS: Of the 35 screened patients, 24 were enrolled and randomized: 12 received efgartigimod and 12 placebo. Efgartigimod was well-tolerated in all patients, with no serious or severe adverse events reported, no relevant changes in vital signs or ECG findings observed, and no difference in adverse events between efgartigimod and placebo treatment. All patients treated with efgartigimod showed a rapid decrease in total immunoglobulin G (IgG) and anti-AChR autoantibody levels, and assessment using all 4 efficacy scales consistently demonstrated that 75% showed a rapid and long-lasting disease improvement. CONCLUSIONS: Efgartigimod was safe and well-tolerated. The correlation between reduction of levels of pathogenic IgG autoantibodies and disease improvement suggests that reducing pathogenic autoantibodies with efgartigimod may offer an innovative approach to treat MG. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that efgartigimod is safe and well-tolerated in patients with gMG.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Howard JF, Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019. PMID: 31118245. doi:10.1212/WNL.0000000000007600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。